Tandem Diabetes Care (TNDM) Competitors $11.97 +0.92 (+8.34%) As of 01:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TNDM vs. LIVN, WRBY, INSP, LQDA, PRCT, LMAT, AORT, EYE, ENOV, and CNMDShould you be buying Tandem Diabetes Care stock or one of its competitors? The main competitors of Tandem Diabetes Care include LivaNova (LIVN), Warby Parker (WRBY), Inspire Medical Systems (INSP), Liquidia Technologies (LQDA), PROCEPT BioRobotics (PRCT), LeMaitre Vascular (LMAT), Artivion (AORT), National Vision (EYE), Enovis (ENOV), and CONMED (CNMD). These companies are all part of the "medical equipment" industry. Tandem Diabetes Care vs. Its Competitors LivaNova Warby Parker Inspire Medical Systems Liquidia Technologies PROCEPT BioRobotics LeMaitre Vascular Artivion National Vision Enovis CONMED Tandem Diabetes Care (NASDAQ:TNDM) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership. Do analysts recommend TNDM or LIVN? Tandem Diabetes Care currently has a consensus target price of $22.47, suggesting a potential upside of 87.88%. LivaNova has a consensus target price of $59.71, suggesting a potential upside of 7.33%. Given Tandem Diabetes Care's higher probable upside, equities analysts clearly believe Tandem Diabetes Care is more favorable than LivaNova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tandem Diabetes Care 0 Sell rating(s) 11 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.27LivaNova 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of TNDM or LIVN? 97.6% of LivaNova shares are owned by institutional investors. 1.9% of Tandem Diabetes Care shares are owned by insiders. Comparatively, 0.3% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is TNDM or LIVN more profitable? LivaNova has a net margin of -16.13% compared to Tandem Diabetes Care's net margin of -20.51%. LivaNova's return on equity of 14.57% beat Tandem Diabetes Care's return on equity.Company Net Margins Return on Equity Return on Assets Tandem Diabetes Care-20.51% -65.40% -13.87% LivaNova -16.13%14.57%6.91% Does the media refer more to TNDM or LIVN? In the previous week, LivaNova had 3 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 9 mentions for LivaNova and 6 mentions for Tandem Diabetes Care. LivaNova's average media sentiment score of 1.53 beat Tandem Diabetes Care's score of 1.03 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tandem Diabetes Care 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has preferable valuation & earnings, TNDM or LIVN? LivaNova has higher revenue and earnings than Tandem Diabetes Care. LivaNova is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTandem Diabetes Care$940.20M0.86-$96.03M-$3.09-3.87LivaNova$1.25B2.42$63.23M-$3.89-14.30 Which has more volatility and risk, TNDM or LIVN? Tandem Diabetes Care has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. SummaryLivaNova beats Tandem Diabetes Care on 12 of the 17 factors compared between the two stocks. Get Tandem Diabetes Care News Delivered to You Automatically Sign up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNDM vs. The Competition Export to ExcelMetricTandem Diabetes CareMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$808.88M$7.05B$5.82B$9.71BDividend YieldN/A1.30%3.84%4.09%P/E Ratio-3.8727.1930.9025.97Price / Sales0.8657.60469.81120.77Price / CashN/A21.6837.1558.38Price / Book6.076.929.116.37Net Income-$96.03M$176.42M$3.26B$265.56M7 Day Performance10.65%0.74%1.85%1.71%1 Month Performance-21.80%-0.31%4.86%1.05%1 Year Performance-71.82%13.26%31.15%20.94% Tandem Diabetes Care Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNDMTandem Diabetes Care4.5442 of 5 stars$11.96+8.2%$22.47+87.9%-74.1%$808.88M$940.20M-3.872,650Analyst ForecastLIVNLivaNova2.6382 of 5 stars$53.27-0.8%$59.29+11.3%+14.2%$2.91B$1.25B-13.692,900Positive NewsAnalyst ForecastWRBYWarby Parker2.2643 of 5 stars$27.38+0.9%$24.06-12.1%+85.6%$2.88B$771.32M-391.093,780Positive NewsINSPInspire Medical Systems4.9313 of 5 stars$88.28+0.6%$165.62+87.6%-51.0%$2.61B$802.80M51.031,246Positive NewsShort Interest ↓LQDALiquidia Technologies3.4999 of 5 stars$27.72+6.8%$31.40+13.3%+173.5%$2.39B$14M-16.3150PRCTPROCEPT BioRobotics3.5392 of 5 stars$40.71-2.1%$74.88+83.9%-52.8%$2.27B$224.50M-26.26430Positive NewsLMATLeMaitre Vascular2.2312 of 5 stars$95.04-0.9%$98.00+3.1%+11.5%$2.15B$219.86M46.14490Positive NewsAORTArtivion3.3982 of 5 stars$42.810.0%$39.80-7.0%+70.0%$2.02B$388.54M-101.921,600Analyst ForecastInsider TradeEYENational Vision2.773 of 5 stars$23.87+5.0%$24.73+3.6%+127.2%$1.89B$1.82B-132.6113,411Positive NewsENOVEnovis4.4712 of 5 stars$29.51-0.1%$51.00+72.8%-33.7%$1.69B$2.11B-2.077,367Positive NewsCNMDCONMED3.9515 of 5 stars$53.35+0.4%$59.80+12.1%-21.9%$1.65B$1.31B15.113,900News Coverage Related Companies and Tools Related Companies LIVN Alternatives WRBY Alternatives INSP Alternatives LQDA Alternatives PRCT Alternatives LMAT Alternatives AORT Alternatives EYE Alternatives ENOV Alternatives CNMD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNDM) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tandem Diabetes Care, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tandem Diabetes Care With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access